Node Positive or High Risk Node negative Triple Negative Breast

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

  • Clinical Trial Information

    Trial Contact: Jobson, Gillian S; Morales, Leticia; Jarquin-Castillo, Katherine

  • IRB No: NRG-BR003

    Protocol Abbrev: NRG-BR003

    Principal Investigator: Nikita Chandrakant Shah, MD

    Phase: Drug: Phase III

    Age Group: Adult

    Treatment: Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT02488967

  • Objective

    To determine if the addition of carboplatin will improve IDFS

  • Key Eligibility

    Early stage triple negative breast cancer